ENTA241220P22500
- 0.00
- 0.000.00%
Enanta Pharmaceuticals Newsroom
Earnings Breakdown: Enanta Pharma Q4
Enanta Pharmaceuticals | 8-K: Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year-Ended September 30, 2024
Press Release: Enanta Pharmaceuticals Reports Financial Results for Its Fiscal Fourth Quarter and Year-Ended September 30, 2024
Enanta Pharmaceuticals 4Q Loss/Shr $1.36 >ENTA
Enanta Pharmaceuticals 4Q Loss $28.8M >ENTA
Enanta Pharmaceuticals 4Q Rev $14.6M >ENTA
Express News | Enanta Pharmaceuticals Q4 Operating Expenses USD 44.461 Million
Express News | Enanta Pharmaceuticals Q4 Net Income USD -28.823 Million Vs. IBES Estimate USD -25.7 Million
Express News | Enanta Pharmaceuticals Q4 Pretax Profit USD -29.186 Million
Express News | Enanta Pharmaceuticals Reports Financial Results for Its Fiscal Fourth Quarter and Year-Ended September 30, 2024
Here Are the Major Earnings After the Close Today
Earnings Scheduled For November 25, 2024
Enanta Pharma's Earnings Outlook
Earnings Preview: ENTA to Report Financial Results Post-market on November 25
The Past Three Years for Enanta Pharmaceuticals (NASDAQ:ENTA) Investors Has Not Been Profitable
Enanta Pharmaceuticals (ENTA): Promising Clinical Stage Biotech With Robust Pipeline
Millennium Management LLC's Strategic Acquisition of Enanta Pharmaceuticals Shares
H.C. Wainwright Maintains Enanta Pharmaceuticals(ENTA.US) With Buy Rating, Maintains Target Price $27
A Glimpse Into The Expert Outlook On Enanta Pharma Through 4 Analysts
Express News | JMP Securities Reiterates Market Outperform on Enanta Pharma, Maintains $22 Price Target